760,073 results match your criteria: "Spain; and Institute Biomedical Research Alberto Sols C.M.M.[Affiliation]"
Alzheimers Dement
December 2024
Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Background: Alzheimer´s disease (AD) is the main cause of death in adults with Down syndrome (DS). We describe the unique contributions of the Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) cohort by studying longitudinal changes in plasma and cerebrospinal fluid (CSF) markers.
Method: We included DABNI participants with DS that contributed at least two plasma and/or CSF samples and were asymptomatic (aDS, n=155), had prodromal AD (pDS, n=46) or had AD dementia (dDS; n=53) at baseline, together with 172 euploid cognitively normal controls (CN).
Alzheimers Dement
December 2024
Department of Clinical Sciences Lund, Lund University, Lund, Lund, Sweden.
Background: The medial temporal lobe (MTL) is the epicenter of both primary and concomitant molecular pathologies in Alzheimer's disease (AD). The intricate anatomy of the MTL has been the subject of extensive study over the past two centuries. However, current PET and MRI AD biomarkers use often crude parcellations of the MTL that have not been sufficiently validated vis-à-vis anatomical ground truth.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Background: In murine models, peripheral blood factors have been identified as having either a brain rejuvenating or ageing effect. However, it is unclear whether these blood factors have similar effects in humans. We aimed at testing the association between these blood factors and cognitive performance in cognitively unimpaired (CU) individuals at risk of Alzheimer's disease (AD).
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Background: Blood biomarkers are essential in identifying Alzheimer's disease (AD) pathology. To ensure their clinical use, it is crucial to understand pre-analytical factors such as fasting conditions and long-term storage at -80°C. This study evaluates the effect of these factors on plasma biomarker concentrations for detecting AD pathology and neurodegeneration.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Janssen Research & Development, LLC, a Johnson & Johnson company, Boston, MA, USA.
Background: Precision neuroscience is emerging as a transformative approach that aims to identify the right treatment for the right patient at the right time. To enable this, it is important to move beyond the categorization of patients based on clinical symptoms towards a biological definition of disease. For Alzheimer's disease, significant progress has been made in this direction, with the development of the "A/T/N" biomarker framework that classifies patients based on underlying pathophysiology.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Hospital Clínic de Barcelona - Fundació de Recerca Clínic Barcelona - IDIBAPS - University of Barcelona, Barcelona, Catalonia, Spain.
Background: Alzheimer's disease (AD) features a complex interplay of factors influencing cognitive decline. While CSF and plasma biomarkers have widely demonstrated their diagnostic utility, whether they may add prognostic value remains unrevealed. With this longitudinal study we aim to address this knowledge gap by evaluating the predictive value of several fluid biomarkers over cognitive decline in a cohort of biomarker-confirmed AD individuals.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Background: To date, limited data exist concerning the utility of FDG-PET in detecting Alzheimer's Disease (AD) in Down Syndrome (DS). Yet, sensitive biomarkers for neurodegeneration are essential in this population genetically predisposed for AD. Therefore, we aimed at characterizing the effect of age, disease stage and AD pathology on brain metabolism in a large cohort of adults with DS.
View Article and Find Full Text PDFBackground: Primary progressive aphasia (PPA) is a language-based dementia linked with underlying Alzheimer's disease (AD) or frontotemporal dementia. Clinicians often report difficulty differentiating between the logopenic (lv) and nonfluent/agrammatic (nfv) subtypes, as both variants present with disruptions to "fluency" yet for different underlying reasons. In English, acoustic and linguistic markers from connected speech samples have shown promise in machine learning (ML)-based differentiation of nfv from lv.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Background: Amyloid β (Aβ) deposition in the brain is a pathological hallmark of Alzheimer's disease (AD). While immunoprecipitation-mass spectrometry (IP-MS) stands out as an accurate method for quantifying blood-based Aβ peptides, its major limitations such as prolonged sample preparation, extensive analysis time, large specimen volume, and high costs, present opportunities for improvement. Consequently, we aimed to develop a novel plasma IP-MS Aβ assay that employs simplified and significantly shorter analytical procedures, along with much-reduced sample volumes.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Neuropsychiatric Institute, Prince of Wales Hospital, Randwick, NSW, Australia.
Background: High-income countries (HICs) are over-represented in current global dementia incidence rates, skewing estimates. Variance in diagnostic methods between HICs and low- and middle-income countries (LMICs) is speculated to contribute to the regional differences in rates. Cohort Studies of Memory in an International Consortium (COSMIC) offers a unique opportunity to address these research inequalities by harmonising data from international studies, including representation from LMICs.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Background: Poor sleep is associated with cognitive decline, and ∼45% of Alzheimer's disease (AD) patients experience sleep disturbances. Emerging evidence suggests that reduced non-rapid eye movement (NREM) slow wave sleep (SWS) is linked to amyloid accumulation and APOE ε4-related genetic vulnerability to AD. Here, we investigate the effects of amyloid and APOE status on SWS, and their interaction, in a cohort of cognitively unimpaired (CU) individuals at higher risk of AD.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Neurology Department, Hospital Quirónsalud Madrid, Madrid, Madrid, Spain.
Background: Identifying individuals with early Alzheimer's disease, i.e. mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) can facilitate the rapid initiation of pharmacological and non-pharmacological therapies with the aim of achieving better clinical outcomes.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Aging Research Center, Karolinska Institutet, Stockholm, Sweden.
Background: Pro-inflammatory diets have been associated with cognitive decline and dementia, but their impact on overall brain aging is unclear. We aimed to investigate the relationship between a pro-inflammatory diet and a machine learning-based measure of brain age, taking into account age, genetic risk for Alzheimer's disease (AD), and systemic inflammation.
Method: From the UK Biobank, 21,473 participants aged 40-70 years and free of chronic brain diseases were included.
Pediatr Allergy Immunol
January 2025
Department of Pediatrics, University Hospitals Leuven, Leuven, Belgium.
Alzheimers Dement
December 2024
Fundación CITA-Alzhéimer Fundazioa, San Sebastian, Spain.
Background: Sex and gender affect Alzheimer's and Dementia differently. Some studies show that women are diagnosed at a later stage. This represents an essential challenge for healthcare and makes research challenging as gender biases may impact participant selection for clinical trials.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Center for Life Ethics, University of Bonn, Bonn, Germany.
Background: In recent years, research on risk estimation and early detection of Alzheimer's disease (AD) advanced swiftly. Studies are investigating the likelihood of developing Alzheimer's dementia (ADD), even during asymptomatic, preclinical, and prodromal stages of AD. Particular hope is pinned on blood-based biomarkers as these are less invasive than other methods such as lumbar puncture and Positron Emission Tomography (PET)-scan.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of California, San Francisco, San Francisco, CA, USA.
Background: over the past decade, a bi-directional relationship between sleep and Alzheimer's disease (AD) has been increasingly recognized, with several studies suggesting a link between self-reported sleep disturbances and AD biomarkers. However, the association between polysomnography (PSG)-assessed sleep parameters and AD biomarkers remains unknown.
Method: We examined 128 participants [mean age 70.
Alzheimers Dement
December 2024
School of Public Health, the Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Background: To estimate the additive associations of cardiometabolic multimorbidity (CMM) and depression on long-term cognitive trajectory in multi-regional cohorts and validate the generalizability of the findings in varying clinical settings.
Method: Data harmonization was performed across 14 longitudinal cohort studies within the Cohort Studies of Memory in an International Consortium (COSMIC) group, spanning North America, South America, Europe, Africa, Asia, and Australia. Three external validation studies with distinct settings were employed to assess generalizability.
Alzheimers Dement
December 2024
Department of Medicine, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, Barcelona, Spain. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Background: Cognitive reserve (CR) and Brain Maintenance (BR) are constructs defined at a theoretical level (Stern et al., Neurobiol Aging, 2021 Apr, 124:100-103). Our aim was to propose a reproducible procedure to compare CR-like of BR-like mechanisms underlying interindividual differences in memory stability.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Faculty of Sport Sciences, Sport and Health University Research Institute (iMUDS), University of Granada., Granada, Granada, Spain.
Regular exercise has been shown to have beneficial effects including reducing risk of developing Alzheimer's disease (AD). However, it is unclear if exercise has direct effects on AD pathophysiology. To this end, several emerging initiatives have been established to investigate plasma biomarker changes in relation to exercise among older adults.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain.
Background: The extended life expectancy in individuals with Down Syndrome (DS) has led to the emergence of age-related diseases, with Alzheimer's disease (AD) being particularly noteworthy due to its nearly full penetrance. The level of intellectual disability (ID), regarded as a proxy for cognitive reserve (CR), explains heterogeneity in cognitive and functional abilities. Despite this, there is a notable lack of exploration into the characterization of resilience factors and their potential influence on the progression along the AD continuum in this population.
View Article and Find Full Text PDFMult Scler
January 2025
Institute of Neurology, University College London, London, UK.
Alzheimers Dement
December 2024
Integrative Pharmacology and Systems Neurosciences Research Group, Neurosciences Research Program, Hospital del Mar Research Institute, Barcelona, Spain.
Background: Lifestyle interventions targeting multiple Alzheimer's disease (AD) risk factors are effective strategies to prevent cognitive decline. Emerging evidence suggests synergistic effects between various intervention components, including lifestyle modifications, supplements, and pharmacological approaches. The PENSA study, part of the World-Wide FINGERs network, is a randomized, double-blind clinical trial following the Finger 2.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Instituto de Investigación Biosanitaria (ibs.GRANADA), Granada, Spain; Faculty of Sport Sciences, Sport and Health University Research Institute (iMUDS), University of Granada., Granada, Granada, Spain; CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Granada, Spain.
In the quest to combat Alzheimer's disease (AD), physical exercise has emerged as one of the leading non-pharmaceutical approaches to improve executive function and ameliorate cognitive decline. The limited understanding of the mechanisms by which exercise impacts cognition in late adulthood hinders the widespread use of exercise as a therapeutic or preventive approach for AD. This underscores the urgent need for research aimed at unraveling the mechanisms by which exercise improves cognition.
View Article and Find Full Text PDFRev Esp Enferm Dig
January 2025
Digestive Medicine, Hospital Clínico Universitario de Valencia .
We report the case of a 38-year-old woman with a 10-year history of ulcerative proctosigmoiditis. Two months after traveling to Morocco, she developed gastrointestinal symptoms accompanied by eosinophilia in blood tests. Four months later, she progressed to systemic illness with pulmonary involvement.
View Article and Find Full Text PDF